DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20191575

Comparison of efficacy and safety of oral azithromycin and oral doxycycline in acne vulgaris

Marya Ahsan, Rahul Ranjan, Shalini Chandra, Kumar Mayank

Abstract


Background: Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit with considerable psychosocial impact. Oral azithromycin or oral doxycycline can be used for the management of moderate and severe acne vulgaris. However, there is no consensus on which antibiotic is superior and the optimal dose for management.

Methods: A prospective randomized interventional study was carried out among 120 patients of moderate to severe acne vulgaris. The patients were randomized into group A and B. While group A was prescribed oral azithromycin 500 mg three times a week, group B was given oral doxycycline 100 mg daily for 12 weeks. Topical clindamycin twice daily application was also given. Global Acne Grading Scale (GAGS) score was recorded at baseline and at 2nd, 4th, 8th and 12th weeks.

Results: GAGS score at baseline in azithromycin (n = 53) and doxycycline (n = 55) group was 31.98±4.49 and 30.63±3.78 respectively (p value >0.05). 83.91±6.83% (p <0.001) and 81.87±6.75% (p <0.001) improvement was seen in azithromycin group and doxycycline group after 12 weeks of treatment. However, there was no difference in the GAGS score between the groups at any follow-up (p value >0.05). 15.09% patients in azithromycin group and 20% patients in doxycycline group reported adverse effects. The most commonly reported adverse effect was diarrhoea. All adverse effects were of ‘mild’ category and causality assessment was ‘possible’.

Conclusions: Oral azithromycin is equally efficacious but safer alternative to oral doxycycline for the management of acne vulgaris.


Keywords


Azithromycin, Daily dosing, Doxycycline, Efficacy, Global acne grading scale, Pulse dosing

Full Text:

PDF

References


Dawson AL, Dellavalle RP. Acne Vulgaris. Br Med J. 2013;346(7907):30-3.

Pooja M, Holla R, Girisha B, Puneeth A. A study of prescription pattern in the drug therapy of acne vulgaris at a tertiary care hospital in Mangalore, India. Int J Basic Clin Pharmacol. 2017;7(1):80-6.

Brar BK, Kumar S, Sethi N. Comparative evauation of dapsone 5% gel vs. clindamycin 1% gel in mild to moderate acne vulgaris. Gulf J Dermatol Venereol. 2016;23(1):34-9.

Adityan B, Thappa DM. Profile of acne vulgaris-A hospital-based study from South India. Indian J Dermatol Venereol Leprol. 2009;75(3):272-8.

Gieler U, Gieler T, Kupfer J. Acne and quality of life–impact and management. J Eur Acad Dermatol Venereol. 2015;29(4):12-4.

Loney T, Standage M, Lewis S. Not Just Skin Deep' Psychosocial Effects of Dermatological-related Social Anxiety in a Sample of Acne Patients. J Health Psychol. 2008;13(1):47-54.

Rathi SK. Acne vulgaris treatment: the current scenario. Indian J Dermatol. 2011;56(1):7-13.

Rumman N. A Review on the Advances in the Treatment of Moderate to Severe Acne Vulgaris. J Dermatol Res Ther. 2016:26-36.

Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017;18(4):469-90.

Balaji A, Rashmi K, Devinder M. Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol. 2009;75(3):323-6.

Srinivasan R, Ramya G. Adverse drug reaction-causality assessment. Int J Res Pharm Chem. 2011;1(3):606-12.

Zaki SA. Adverse drug reaction and causality assessment scales. Lung India. 2011;28(2):152-3.

MacDougall C. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Brunton LB, Lazo JS, Parker KL, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th edition. New York, NY: McGraw-Hill; 2018:1054-70.

Babu M. Case Report: Treatment With Azithromycin For Acne Vulgaris: The Current Scenario. Imperial J Interdiscipl Res. 2016;2(7):292-5.

Kapadia N, Talib A. Acne treated successfully with azithromycin. Int J Dermatol. 2004;43(10):766-7.

Kircik LH. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol. 2010;9(11):1407-11

Parsad D, Pandhi R, Nagpal R, Negi K. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol. 2001;28(1):1-4.

Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatol Treat. 2006;17(4):217-21.

Kumar VK. A comparative study on the efficacy and safety of oral azithromycin pulse versus doxycycline daily in the treatment of acne vulgaris. J Evid Based Med Healthcare. 2017;4(90):5410-3.

Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000;39(1):45-50.